Publications

5891 Results

KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536

Authors
PC Mack;WS Holland;M Redman;P Lara;LJ Snyder;FR Hirsch;WA Franklin;ES Kim;RS Herbst;DR Gandara
Journal / Conference
Journal of Clinical Oncology 27:15s, abst. #8022
Year
2009
Research Committee(s)
Lung
Study Number(s)
S0342, S0536

Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP)

Authors
SM Schuetze;P Rutkowski;M Van Glabbeke;C Rankin;BP Rubin;A Lazar;M Debiec-Rychter;H Gelderblom;P Hohenberger;A Van Oosterom
Journal / Conference
Journal of Clinical Oncology 27:15s, abst. #10520
Year
2009
Research Committee(s)
Sarcoma
Study Number(s)
S0345

Carboplatin, paclitaxel, cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study

Authors
DR Gandara;ES Kim;RS Herbst;J Moon;M Redman;SR Dakhil;F Hirsch;PC Mack;WA Franklin;K Kelly
Journal / Conference
Journal of Clinical Oncology 27:15s, abst.#8015
Year
2009
Research Committee(s)
Lung
Study Number(s)
S0536

Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): update of Intergroup Francophone du Myeloma (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials

Authors
B Barlogie;M Attal;J Crowley;J Harousseau
Journal / Conference
Journal of Clinical Oncology 27:15s, abst. #8519
Year
2009
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): examining whether different variables govern different time segments of survival

Authors
J Crowley;V Bolejack;K Robert;K Anderson;B Barlogie
Journal / Conference
Journal of Clinical Oncology 27:15s, abst. #8599
Year
2009
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma

Authors
L Swinnen;C Rankin;EJ Rushing;HF Laura;DM Damek;GR Barger
Journal / Conference
Journal of Clinical Oncology 27:15s, abst.#2063
Year
2009
Research Committee(s)
Brain
Study Number(s)
S9811

Does quality of treatment-related harms reporting affect conclusions about superiority of treatment?

Authors
RS Mhaskar;A Kumar;H Soares;M Schell;B Djulbegovic
Journal / Conference
Journal of Clinical Oncology 27:15s, abst.#6607
Year
2009
Research Committee(s)
Multiple sites

Cooperative group trials - Southwest Oncology Group (SWOG) innovations in advanced prostate cancer [PMID21085622; PMC2981166]

Authors
TB Dorff;C Tangen;ED Crawford;DP Petrylak;CS Higano;D Raghavan;DI Quinn;NJ Vogelzang;IM Thompson;MHA Hussain
Journal / Conference
Therapeutic Advances in Medical Oncology 1(2):69-77;
Year
2009
Research Committee(s)
Genitourinary
Study Number(s)
S0032, S0111, S0354, S0418, S0421, SWOG-8219, SWOG-8494 (INT-0036), SWOG-8894 (INT-0105) (EST-2889), SWOG-9346, SWOG-9407, SWOG-9426, S9916

Variants in the BRCA1/Fanconi-Anemia repair pathway and taxane-induced neuropathy in SWOG directed intergroup study S0221

Authors
LE Sucheston;H Zhao;S Yao;W Barlow;DL Hershman;GT Budd;W Davis;G Ciupak;J Stewart;C Isaacs;T Hobday;J Latreille;G Hortobagyi;J Gralow;R Livingston;K Albain;DF Hayes;CB Ambrosone
Journal / Conference
San Antonio Breast Cancer Symposium, 2009, poster presentation, abst. #2001
Year
2009
Research Committee(s)
Breast
Study Number(s)
S0221

Cetuximab (C225) plus cisplatin (CDDP), irinotecan (CPT11) and thoracic radiotherapy (TRT as definitive treatment for locally advanced, clinically unresectable esophageal cancer (EC): a Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0414)

Authors
CR Thomas;B Goldman;J Benedetti;HJ Lenz;T Baker;L Hammond-Thelin;VK Mehta;C Fenoglio-Preiser;J Abbruzzese;CD Blanke
Journal / Conference
International Journal of Radiation Oncology, Biology & Physics 75(3)supl., abst #1094, S168. ASTRO poster discuss.
Year
2009
Research Committee(s)
Gastrointestinal
Study Number(s)
S0414